ARWR
Arrowhead Pharmaceuticals, Inc.
Biotechnology · Healthcare · United States
59.90
close · 2026-10-30
value
78
cheaper than peers78
quality
13
stronger fundamentals13
ranked against
Biotechnology (commercial)
value
quality
162 peerswide variation
Value inputs
| measure | company | vs peers |
| cash flow yield, latest year | 1.9% | 86 |
| earnings yield, 2 years ago | -3.2% | 81 |
| earnings yield, 3 years ago | -2.8% | 80 |
| earnings yield, latest year | -0.0% | 79 |
| cash flow yield, 3 years ago | -2.2% | 74 |
| cash flow yield, 2 years ago | -3.9% | 69 |
| earnings yield, 1 year ago | -8.3% | 63 |
| cash flow yield, 1 year ago | -7.1% | 59 |
| price to sales | 13.60× | 44 |
| price to book | 18.16× | 11 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| return on equity | -42.4% | 56 |
| operating margin | -191.6% | 46 |
| debt to equity | 231.0% | 10 |
| revenue growth | -86.4% | 7 |
4 of 4 measures available
Facts
| market cap | $8B |
| free cash flow | -$46.1M |
| employees | 711 |
| first trade | 1993-12-16 |
| next earnings | 2026-08-04 |
| fundamentals updated | 2026-08-05 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -0.01 | -5.00 | -1.92 | -1.67 |
| free cash flow | $156.9M | -$604.3M | -$330.6M | -$188.9M |
| net income | -$1.6M | -$599.5M | -$205.3M | -$176.1M |
| revenue | $829.4M | $3.6M | $240.7M | $243.2M |